Shanghai Junshi Biosciences Co. Ltd
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of malignant tumors, neurological, autoimmune, chronic metabolic, nervous system, and infectious diseases in the People's Republic of China. The company was founded in 2012 and is headquartered in Shanghai, People's Republic of … Read more
Shanghai Junshi Biosciences Co. Ltd (SHJBF) - Net Assets
Latest net assets as of September 2025: $6.29 Billion USD
Based on the latest financial reports, Shanghai Junshi Biosciences Co. Ltd (SHJBF) has net assets worth $6.29 Billion USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($11.68 Billion) and total liabilities ($5.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.29 Billion |
| % of Total Assets | 53.86% |
| Annual Growth Rate | 33.95% |
| 5-Year Change | 1.87% |
| 10-Year Change | 868.75% |
| Growth Volatility | 66.37 |
Shanghai Junshi Biosciences Co. Ltd - Net Assets Trend (2014–2024)
This chart illustrates how Shanghai Junshi Biosciences Co. Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Junshi Biosciences Co. Ltd (2014–2024)
The table below shows the annual net assets of Shanghai Junshi Biosciences Co. Ltd from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $5.95 Billion | -18.94% |
| 2023-12-31 | $7.34 Billion | -24.92% |
| 2022-12-31 | $9.78 Billion | +17.33% |
| 2021-12-31 | $8.33 Billion | +42.64% |
| 2020-12-31 | $5.84 Billion | +95.46% |
| 2019-12-31 | $2.99 Billion | -10.02% |
| 2018-12-31 | $3.32 Billion | +196.71% |
| 2017-12-31 | $1.12 Billion | -0.65% |
| 2016-12-31 | $1.13 Billion | +83.42% |
| 2015-12-31 | $614.22 Million | +92.02% |
| 2014-12-31 | $319.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Junshi Biosciences Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1029177706100.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $985.69 Million | 16.77% |
| Other Comprehensive Income | $-159.94 Million | -2.72% |
| Other Components | $15.38 Billion | 261.56% |
| Total Equity | $5.88 Billion | 100.00% |
Shanghai Junshi Biosciences Co. Ltd Competitors by Market Cap
The table below lists competitors of Shanghai Junshi Biosciences Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Shanghai Baosight Software Co Ltd B
SHG:900926
|
$1.38 Billion |
|
JetBlue Airways Corp
NASDAQ:JBLU
|
$1.38 Billion |
|
Guangdong Create Century Intelligent Equipment Group Corp Ltd
SHE:300083
|
$1.38 Billion |
|
Lien Hwa Industrial Corp
TW:1229
|
$1.38 Billion |
|
Orchid Island Capital Inc.
NYSE:ORC
|
$1.38 Billion |
|
Talos Energy Inc
F:7T2
|
$1.38 Billion |
|
Kalpataru Projects International Ltd.
NSE:KPIL
|
$1.38 Billion |
|
CMB.TECH NV
NYSE:CMBT
|
$1.38 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Junshi Biosciences Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 7,170,822,000 to 5,878,551,000, a change of -1,292,271,000 (-18.0%).
- Net loss of 1,282,398,000 reduced equity.
- Dividend payments of 73,790,126 reduced retained earnings.
- Share repurchases of 4,001,000 reduced equity.
- Other comprehensive income decreased equity by 17,870,046.
- Other factors increased equity by 85,788,172.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-1.28 Billion | -21.81% |
| Dividends Paid | $73.79 Million | -1.26% |
| Share Repurchases | $4.00 Million | -0.07% |
| Other Comprehensive Income | $-17.87 Million | -0.3% |
| Other Changes | $85.79 Million | +1.46% |
| Total Change | $- | -18.02% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Junshi Biosciences Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.33x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 1.34x to 0.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $1.47 | $1.97 | x |
| 2015-12-31 | $2.72 | $1.97 | x |
| 2016-12-31 | $1.48 | $1.97 | x |
| 2017-12-31 | $1.47 | $1.97 | x |
| 2018-12-31 | $5.52 | $1.97 | x |
| 2019-12-31 | $3.81 | $1.97 | x |
| 2020-12-31 | $7.08 | $1.97 | x |
| 2021-12-31 | $8.92 | $1.97 | x |
| 2022-12-31 | $10.34 | $1.97 | x |
| 2023-12-31 | $7.29 | $1.97 | x |
| 2024-12-31 | $5.97 | $1.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Junshi Biosciences Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -21.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -65.82%
- • Asset Turnover: 0.18x
- • Equity Multiplier: 1.84x
- Recent ROE (-21.81%) is below the historical average (-20.06%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -8.01% | -435.27% | 0.02x | 1.06x | $-56.78 Million |
| 2015 | -9.55% | -2008.12% | 0.00x | 1.03x | $-118.70 Million |
| 2016 | -11.70% | -3512.56% | 0.00x | 1.02x | $-244.72 Million |
| 2017 | -28.63% | -27948.08% | 0.00x | 1.09x | $-432.89 Million |
| 2018 | -21.56% | -76703.85% | 0.00x | 1.28x | $-1.05 Billion |
| 2019 | -24.89% | -95.98% | 0.18x | 1.48x | $-1.04 Billion |
| 2020 | -28.52% | -104.44% | 0.20x | 1.37x | $-2.25 Billion |
| 2021 | -9.03% | -17.85% | 0.36x | 1.39x | $-1.51 Billion |
| 2022 | -25.16% | -164.16% | 0.12x | 1.32x | $-3.33 Billion |
| 2023 | -31.82% | -151.85% | 0.13x | 1.58x | $-3.00 Billion |
| 2024 | -21.81% | -65.82% | 0.18x | 1.84x | $-1.87 Billion |
Industry Comparison
This section compares Shanghai Junshi Biosciences Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Junshi Biosciences Co. Ltd (SHJBF) | $6.29 Billion | -8.01% | 0.86x | $1.38 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |